SOLICITATION NOTICE
Q -- Quantify and Scan DNA Samples on Customer's Illumina OmniExpress Chips
- Notice Date
- 8/17/2015
- Notice Type
- Presolicitation
- NAICS
- 621511
— Medical Laboratories
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 9609 Medical Center Drive, Room 1E128, Rockville, Maryland, 20852, United States
- ZIP Code
- 20852
- Solicitation Number
- N02CP52670-76
- Archive Date
- 8/28/2015
- Point of Contact
- Catherine Muir, Phone: (240) 276-5434
- E-Mail Address
-
muirca@mail.nih.gov
(muirca@mail.nih.gov)
- Small Business Set-Aside
- N/A
- Description
- Contracting Office Address: Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 9609 Medical Center Drive, Room 1E144, Bethesda, MD 20892, UNITED STATES Description: National Cancer Institute (NCI), Div. of Cancer Epidemiology and Genetics (DCEG), Occupational and Environmental Epidemiology Branch (OEEB), plans to procure on a sole source basis the laboratory services to quantify and scan DNA samples on Customer's Illumina OmniExpress Chips from BEIJING GENE-SQUARE BIOTECH LTD., Room 207, Tower C, Shu Guang Building, No. 5 Jing Shun Road, Chao Yang District, Beijing, China 100028. The response close date of this notice for this requirement is in accordance with FAR 5.203(a)(1). This acquisition will be processed under FAR Part 12 - Acquisition for Commercial Items and in accordance with simplified acquisition procedures as stated in FAR Part 13.106-1(b)(1), and is exempt from the requirements of FAR Part 6. The North American Industry Classification System code is 621511 and the business size standard is $32.5M. Only one award will be made as a result of this solicitation. This will be awarded as a firm fixed price, type contract. The period of performance will be twelve (12) months from date of award. It has been determined there are no opportunities to acquire green products or services for this procurement. The Division of Cancer Epidemiology and Genetics (DCEG) is a research program of the National Cancer Institute (NCI), one of the National Institutes of Health (NIH). The Division is the world's most comprehensive cancer epidemiology research group. Its renowned epidemiologists, geneticists, and biostatisticians conduct population and multidisciplinary research to discover the genetic and environmental determinants of cancer and new approaches to cancer prevention. The Division's research impacts public health policy in the United States and around the world. The Occupational and Environmental Epidemiology Branch (OEEB) conducts studies in the United States and abroad to identify and evaluate environmental and workplace exposures that may be associated with cancer risk. The contribution of environmental, occupational and genetic factors to leukemia has generated a series of novel, cutting edge findings in studies of Caucasians. However, the ability to follow-up, confirm, and extend these observations has become limited by the low prevalence and limited range of several important chemical exposures and the high to complete linage disequilibrium between key candidate genetic loci in Western populations. To optimize the ability to build on and clarify these finding, it is necessary to investigate populations that differ from Caucasians in both exposure patterns and underlying genetic structure. Thus, it's valuable to scan DNA from several hospital-based case-control studies of leukemia in East Asia, including an on-going hospital-based case control studies carrying out by the NCI (Asia Lymph). The major postulated risk factors for evaluation in this study are chemical exposures (e.g. benzene), genetic susceptibility and infectious agents. This study should confirm and extend previous findings, and yield novel insights into the causes of leukemia in both Asia and the West. The Contractor shall perform the following tasks for 820 DNA samples: 1. Quantify DNA samples and adjust concentration as needed 2. Scan DNA samples on Illumina OmniExpress chips, to be provided by the NCI. Government Responsibilities: 820 DNA samples from studies of leukemia in China will be shipped to the Contractor. Samples will not have any personal identifiers attached. In addition, the NCI will ship to the Contractor enough Illumina OmniExpress 750K chips and reagents to scan the 820 DNA samples. Reporting Requirement and Deliverables: The Contractor shall call the NCI Contracting Officer's Representative (COR) biweekly to report the number of samples processed. The Contractor shall deliver to the NCI COR the results of the scanned DNA samples by uploading the data files to a site to be set up by the NCI. Inspection and acceptance criteria: The NCI will have fifteen (15) business days in which to review and accept these data. If no comments or request for revisions are provided within fifteen (15) business days the deliverables shall be considered acceptable. This laboratory service is provided by BEIJING GENE-SQUARE BIOTECH LTD. Gene-square is an Illumina's certified service provider, and is the highest-quality service provider in China. China has imposed restrictions on the export of DNA samples if a lab within China can conduct the similar task to the ones out of the country. Therefore, a lab in China needs to conduct scanning DNA samples collected in China. In addition, the identified lab must be able and willing to accept the chips and reagents that will be provided by the NCI to perform this work. Market research identified the proposed Vendor as the only Vendor in China that can provide this service, and is willing and able to use the NCI-provided chips and reagents (rather than using its own chips). Further, the Beijing Gene-Square Biotech laboratory has previously analyzed DNA samples from cases and controls for the NCI lung cancer and lymphoma studies carried out in China. Using the same method, the Beijing laboratory will analyze DNA samples from the NCI's study of leukemia in Eastern Asia. It is critically important that Gene-square analyze these samples so that the OEEB can use data from control patients from the lymphoma study, which were scanned by Gene-square for the previous NCI study, as the comparison group for the 820 new cases that will be scanned under this procurement. This will ensure that the new data is scientifically comparable to previous data generated by Gene-Square. If the same analysis is not used, the NCI will not be able to combine and compare the results of the two (2) studies. The performance characteristics and quality of the needed services, uniquely provided by the proposed Vendor are required for maintaining the integrity of on-going studies, and a change would be disruptive. This notice is not a request for competitive quotation. However, if any interested party, especially small businesses, believes it can meet the above requirement, it may submit a capability statement, proposal, or quotation, which shall be considered by the agency. The statement of capabilities and any other information furnished must be in writing and must contain material in sufficient detail to allow the NCI to determine if the party can perform the requirement. Responses must be received in the contracting office by 1:30PM EDT, on Aug. 27, 2015. All responses and questions must be in writing and faxed (240) 276-5401 or emailed to Catherine Muir, Contracting Officer via electronic mail at muirca@mail.nih.gov. A determination by the Government not to compete this proposed requirement based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. No collect calls will be accepted. In order to receive an award, Contractors must be registered and have valid, current Entity Record, including current Representations and Certifications, in the System for Award Management (SAM) through SAM.gov. Reference: N02CP52670-76 on all correspondence.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/RCB/N02CP52670-76/listing.html)
- Record
- SN03842016-W 20150819/150817235336-60b1c0dcabc1313081904bb37c7657b9 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |